Monocyte-derived dendritic cell (DC)-based vaccines loaded with tumor self-antigens represent a novel approach in anticancer therapy. We evaluated DC-based anticancer immunotherapy (ITx) in an academic Phase I/II clinical trial for children, adolescent, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors. The primary endpoint was safety of intradermal administration of manufactured DCs. Here, we focused on relapsing high-risk sarcoma subgroup representing a major diagnosis in DC clinical trial. As a part of peripheral blood immunomonitoring, we evaluated quantitative association between basic cell-based immune parameters. Furthermore, we describe the pattern of these parameters and their time-dependent variations during the DC vaccination in the peripheral blood immunograms. The peripheral blood immunograms revealed distinct patterns in particular patients in the study group. As a functional testing, we evaluated immune response of patient T-cells to the tumor antigens presented by DCs in the autoMLR proliferation assay. This analysis was performed with T-cells obtained prior to DC ITx initiation and with T-cells collected after the fifth dose of DCs, demonstrating that the anticancer DC-based vaccine stimulates a preexisting immune response against self-tumor antigens. Finally, we present clinical and immunological findings in a Ewing's sarcoma patient with an interesting clinical course. Prior to DC therapy, we observed prevailing CD8+ T-cell stimulation and low immunosuppressive monocytic myeloid-derived suppressor cells (M-MDSC) and regulatory T-cells (Tregs). This patient was subsequently treated with 19 doses of DCs and experienced substantial regression of metastatic lesions after second disease relapse and was further rechallenged with DCs. In this patient, functional ex vivo testing of autologous T-cell activation by manufactured DC medicinal product during the course of DC ITx revealed that personalized anticancer DC-based vaccine stimulates a preexisting immune response against self-tumor antigens and that the T-cell reactivity persisted for the period without DC treatment and was further boosted by DC rechallenge. Trial Registration Number: EudraCT 2014-003388-39.

Department of Laboratory Medicine Masaryk Memorial Cancer Institute Brno Czechia

Department of Nuclear Medicine Masaryk Memorial Cancer Institute Brno Czechia

Department of Pediatric Oncology University Hospital and Faculty of Medicine Masaryk University Brno Czechia

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czechia

International Clinical Research Center St Anne's University Hospital Brno Czechia

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czechia

Zobrazit více v PubMed

Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, et al. . A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. (2008) 14:4850–8. 10.1158/1078-0432.CCR-07-4065 PubMed DOI PMC

Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, et al. . Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. (2016) 22:3182–91. 10.1158/1078-0432.CCR-15-2550 PubMed DOI PMC

Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, et al. . Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clin Cancer Res. (2015) 21:3178–86. 10.1158/1078-0432.CCR-14-2932 PubMed DOI PMC

Lewin J, Davidson S, Anderson ND, Lau BY, Kelly J, Tabori U, et al. . Response to immune checkpoint inhibition in two patients with alveolar soft-part sarcoma. Cancer Immunol Res. (2018) 6:1001–7. 10.1158/2326-6066.CIR-18-0037 PubMed DOI

Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z. Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol. (2019) 15:100221. 10.1016/j.jbo.2019.100221 PubMed DOI PMC

Zdrazilova-Dubska L, Valik D, Budinska E, Frgala T, Bacikova L, Demlova R. NKT-like cells are expanded in solid tumour patients. Klin Onkol. (2012) 25 (suppl. 2):2S21–5. 10.14735/amko20122S21 PubMed DOI

Cibulka M, Selingerova I, Fedorova L, Zdrazilova-Dubska L. Immunological aspects in oncology–circulating γδ T-cells. Klin Onkol. (2015) 28 (Suppl. 2):2S60–8. 10.14735/amko20152S60 PubMed DOI

Dohnal AM, Witt V, Hugel H, Holter W, Gadner H, Felzmann T. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. (2007) 9:755–70. 10.1080/14653240701589221 PubMed DOI

Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, et al. . Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res. (2013) 19:1525–33. 10.1158/1078-0432.CCR-12-1879 PubMed DOI

Hlavackova E, Pilatova K, Cerna D, Selingerova I, Mudry P, Mazanek P, et al. Dendritic cell-based immunotherapy in advanced sarcoma and neuroblastoma pediatric patients: anti-cancer treatment preceding monocyte harvest impairs immunostimulatory and antigen-presenting behavior of DCs and manufacturing process outcome. Front Oncol. (2019) 9:1034 10.3389/fonc.2019.01034 PubMed DOI PMC

R_Core_Team . R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; (2019).

Schatorje EJ, Gemen EF, Driessen GJ, Leuvenink J, Van Hout RW, De Vries E. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol. (2012) 75:436–44. 10.1111/j.1365-3083.2012.02671.x PubMed DOI

Pilatova K, Budinska E, Benscikova B, Nenutil R, Sefr R, Fedorova L, et al. . Circulating myeloid suppressor cells and their role in tumour immunology. Klin Onkol. (2017) 30:s166–9. PubMed

Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. (1994) 153:1687–96. PubMed

Kabelitz D, Kalyan S, Oberg HH, Wesch D. Human Vdelta2 versus non-Vdelta2 gammadelta T cells in antitumor immunity. Oncoimmunology. (2013) 2:e23304. 10.4161/onci.23304 PubMed DOI PMC

Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. (2008) 8:523–32. 10.1038/nri2343 PubMed DOI PMC

Sieminska I, Rutkowska-Zapala M, Bukowska-Strakova K, Gruca A, Szaflarska A, Kobylarz K, et al. . The level of myeloid-derived suppressor cells positively correlates with regulatory T cells in the blood of children with transient hypogammaglobulinaemia of infancy. Cent Eur J Immunol. (2018) 43:413–20. 10.5114/ceji.2018.81359 PubMed DOI PMC

Pal S, Nandi M, Dey D, Chakraborty BC, Shil A, Ghosh S, et al. . Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther. (2019) 49:1346–59. 10.1111/apt.15226 PubMed DOI

Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L. Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment. Cancer Immunol Immunother. (2018) 67:1919–29. 10.1007/s00262-018-2166-4 PubMed DOI PMC

Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. (2003) 197:163–8. 10.1084/jem.20021500 PubMed DOI PMC

Holtmeier W, Pfander M, Hennemann A, Zollner TM, Kaufmann R, Caspary WF. The TCR-delta repertoire in normal human skin is restricted and distinct from the TCR-delta repertoire in the peripheral blood. J Invest Dermatol. (2001) 116:275–80. 10.1046/j.1523-1747.2001.01250.x PubMed DOI

Bol KF, Schreibelt G, Gerritsen WR, De Vries IJ, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res. (2016) 22:1897–906. 10.1158/1078-0432.CCR-15-1399 PubMed DOI

Noordam L, Kaijen MEH, Bezemer K, Cornelissen R, Maat L, Hoogsteden HC, et al. . Low-dose cyclophosphamide depletes circulating naive and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. Oncoimmunology. (2018) 7:e1474318. 10.1080/2162402X.2018.1474318 PubMed DOI PMC

Nada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT. Enhancing adoptive cancer immunotherapy with Vgamma2Vdelta2 T cells through pulse zoledronate stimulation. J Immunother Cancer. (2017) 5:9. 10.1186/s40425-017-0209-6 PubMed DOI PMC

Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol. (2011) 18:e150–7. 10.3747/co.v18i3.783 PubMed DOI PMC

Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, et al. . Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. (2016) 5:e1057673. 10.1080/2162402X.2015.1057673 PubMed DOI PMC